Results 71 to 80 of about 8,773 (178)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer   +3 more
wiley   +1 more source

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1137-1161, July 2026.
Autoimmune blistering disorders (AIBDs) in children are rare, challenging to diagnose and treat and often require immunosuppressants. Until now, no paediatric care guidelines existed. The EADV Task Force for AIBDs has developed the consensus‐based recommendations, enabling physicians to adopt a uniform, tailored treatment strategy to improve outcomes ...
A. Nanda   +31 more
wiley   +1 more source

Utilization of Suprathel® in delayed surgical management of toxic epidermal necrolysis (TEN): A case report

open access: yesBurns Open
Given the lack of established practice guidelines for the management of cutaneous symptoms associated with toxic epidermal necrolysis, treatments range from various dressings to skin substitutes.
Isabella Lipkin   +2 more
doaj   +1 more source

A fatal case of cutaneous adverse drug-induced toxic epidermal necrolysis associated with severe rhabdomyolysis

open access: yesAnnals of Saudi Medicine, 2012
Toxic epidermal necrolysis represents an immunologic reaction to a foreign antigen and is most often caused by drugs. Atorvastatin, a blood cholesterol–lowering agent, is a recognized cause of rhabdomyolysis; while naproxen, a widely used nonsteroidal ...
Sheik Oaleed Noordally   +5 more
doaj   +1 more source

Clinical Images: Skin manifestations and radiographic findings of anti‐SAE1 positive dermatomyositis

open access: yes
ACR Open Rheumatology, Volume 8, Issue 7, July 2026.
Amara Seng   +4 more
wiley   +1 more source

STEVENS-JOHNSON SYNDROME — TOXIC EPIDERMAL NECTROLYSIS IN CHILDREN. PART I. DETERMINATION, ETIOLOGY, PATHOGENESIS, CLINICAL MANIFESTATIONS, SYSTEMIC TREATMENT

open access: yesПедиатрическая фармакология, 2011
Part I of the literature review provides modern terminology and classification of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which is now considered different ways of treating the single pathological process induced in children ...
V.F. Zhernosek, T.P. Dyubkova
doaj   +2 more sources

Multidisciplinary management of antiepileptic drug-induced toxic epidermal necrolysis in a young woman

open access: yesBiomédica: revista del Instituto Nacional de Salud
Toxic epidermal necrolysis is a rare, life-threatening dermatological emergency characterized by extensive epidermal detachment and mucosal involvement,  associated with high morbidity and mortality.
Salman Khan, Priti Singh, Rana Salieva
doaj   +1 more source

Exploring skin adverse events and mechanisms of apalutamide using data mining algorithms and network pharmacology

open access: yesFrontiers in Pharmacology
BackgroundSkin adverse events of apalutamide pose a major challenge to its clinical use, particularly the severe and difficult to identify toxic epidermal necrolysis.
Yaqing Chen   +4 more
doaj   +1 more source

Toxic Epidermal Necrolysis

open access: yesInternational Journal of Clinical Practice, 1967
M J, Samuels, M D, Readett
openaire   +2 more sources

Home - About - Disclaimer - Privacy